Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA approves Novartis’ Rhapsido for CSU treatment
Novartis has obtained approval from the US Food and Drug Administration (FDA) for Rhapsido (remibrutinib) to treat adult patients suffering from chronic spontaneous urticaria (CSU).
Skin Rash
-
01 Oct 2025
-
27 Feb 2023
Timber’s TMB-001 receives orphan drug designation from EC to treat XLRI
Timber Pharmaceuticals has received orphan drug designation from the European Commission (EC) for TMB-001 to treat X-linked recessive ichthyosis (XLRI).